Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-312 first-line tarlatamab combination study in extensive-stage small-cell lung cancer
jRCT2071250047Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Aug 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of tarlatamab in small cell lung cancer (SCLC) (2 arms), sponsored by Amgen. Primary endpoints: Overall Survival and Progression-free Survival (BICR assessed). Started Aug 2025; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2071250047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250047.